MI-503

• CAT Number: I013741
• CAS Number: 1857417-13-0
• Molecular Formula: C₂₈H₂₇F₃N₈S
• Molecular Weight: 564.63
• Purity: ≥95%
• Target: Epigenetic Reader Domain
• Solubility: 10 mM in DMSO
• IUPAC Name: 4-methyl-1-(1H-pyrazol-4-ylmethyl)-5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]indole-2-carbonitrile
• InChI: InChI=1S/C28H27F3N8S/c1-17-19(2-3-25-23(17)8-21(11-32)39(25)14-18-12-35-36-13-18)15-38-6-4-20(5-7-38)37-26-24-9-22(10-28(29,30)31)40-27(24)34-16-33-26/h2-3,8-9,12-13,16,20H,4-7,10,14-15H2,1H3,(H,35,36)(H,33,34,37)
• InChIKey: DETOMBLLEOZTMZ-UHFFFAOYSA-N
• SMILES: CC1=C(C=CC2=C1C=C(N2CC3=CNN=C3)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC=N5)CC(F)(F)F

MI-503(CAT: I013741) is a high-affinity, selective inhibitor of menin-MLL interaction, a critical driver in leukemogenesis. By disrupting the binding of menin to MLL fusion proteins, MI-503 effectively inhibits downstream transcriptional programs associated with acute leukemia. This compound exhibits nanomolar potency in preclinical studies, demonstrating its potential in targeting MLL-rearranged leukemias and other cancers driven by menin-MLL interaction. MI-503 provides a robust tool for studying epigenetic regulation and developing targeted therapies for hematologic malignancies. Its specificity and reliability make it an essential asset in cancer research and drug discovery focused on epigenetic modulators.